{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:37:03Z","timestamp":1791877023784,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As the world continues to experience the COVID-19 pandemic, seasonal influenza remain a cause of severe morbidity and mortality globally. Worse yet, coinfection with SARS-CoV-2 and influenza A virus (IAV) leads to more severe clinical outcomes. The development of a combined vaccine against both COVID-19 and influenza is thus of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we developed and characterized a novel mRNA vaccine encoding the HA antigen of influenza A (H1N1) virus, termed ARIAV. Then, ARIAV was combined with our COVID-19 mRNA vaccine ARCoV, which encodes the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, to formulate the final combined vaccine, AR-CoV\/IAV. Further characterization demonstrated that immunization with two doses of AR-CoV\/IAV elicited robust protective antibodies as well as antigen-specific cellular immune responses against SARS-CoV-2 and IAV. More importantly, AR-CoV\/IAV immunization protected mice from coinfection with IAV and the SARS-CoV-2 Alpha and Delta variants. Our results highlight the potential of the LNP-mRNA vaccine platform in preventing COVID-19 and influenza, as well as other respiratory diseases.<\/jats:p>","DOI":"10.1038\/s41541-022-00478-w","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T05:05:10Z","timestamp":1658811910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Rational development of a combined mRNA vaccine against COVID-19 and influenza"],"prefix":"10.1038","volume":"7","author":[{"given":"Qing","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-980X","authenticated-orcid":false,"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-2807","authenticated-orcid":false,"given":"Cheng-Feng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"478_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (2020)."},{"key":"478_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"478_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"478_CR4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1001\/jama.2020.6266","volume":"323","author":"D Kim","year":"2020","unstructured":"Kim, D., Quinn, J., Pinsky, B., Shah, N. H. & Brown, I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA 323, 2085\u20132086 (2020).","journal-title":"JAMA"},{"key":"478_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/jmv.25953","volume":"92","author":"MD Nowak","year":"2020","unstructured":"Nowak, M. D., Sordillo, E. M., Gitman, M. R. & Paniz Mondolfi, A. E. Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus\/enterovirus? J. Med. Virol. 92, 1699\u20131700 (2020).","journal-title":"J. Med. Virol."},{"key":"478_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","volume":"81","author":"L Lansbury","year":"2020","unstructured":"Lansbury, L., Lim, B., Baskaran, V. & Lim, W. S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect. 81, 266\u2013275 (2020).","journal-title":"J. Infect."},{"key":"478_CR7","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/jmv.26163","volume":"92","author":"H Yue","year":"2020","unstructured":"Yue, H. et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J. Med. Virol. 92, 2870\u20132873 (2020).","journal-title":"J. Med. Virol."},{"key":"478_CR8","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S0140-6736(20)31052-7","volume":"395","author":"E Cuadrado-Pay\u00e1n","year":"2020","unstructured":"Cuadrado-Pay\u00e1n, E. et al. SARS-CoV-2 and influenza virus co-infection. Lancet 395, e84 (2020).","journal-title":"Lancet"},{"key":"478_CR9","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/j.jinf.2020.05.041","volume":"81","author":"X Zheng","year":"2020","unstructured":"Zheng, X. et al. Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China. J. Infect. 81, e128\u2013e129 (2020).","journal-title":"J. Infect."},{"key":"478_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3201\/eid2606.200299","volume":"26","author":"X Wu","year":"2020","unstructured":"Wu, X. et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg. Infect. Dis. 26, 1324\u20131326 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"478_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41422-021-00473-1","volume":"31","author":"L Bai","year":"2021","unstructured":"Bai, L. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 31, 395\u2013403 (2021).","journal-title":"Cell Res."},{"key":"478_CR12","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1038\/s41467-021-26113-1","volume":"12","author":"H Achdout","year":"2021","unstructured":"Achdout, H. et al. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. Nat. Commun 12, 5819 (2021).","journal-title":"Nat. Commun"},{"key":"478_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-021-00618-z","volume":"6","author":"L Bao","year":"2021","unstructured":"Bao, L. et al. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct. Target Ther. 6, 200 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"478_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00809-2","volume":"11","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita, T. et al. Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. Sci. Rep. 11, 21259 (2021).","journal-title":"Sci. Rep."},{"key":"478_CR15","first-page":"JVI0179121","volume":"540","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. SARS-CoV-2 and Influenza A virus Co-infections in Ferrets. J. Virol 540, JVI0179121 (2021).","journal-title":"J. Virol"},{"key":"478_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.abd2220","volume":"368","author":"EA Belongia","year":"2020","unstructured":"Belongia, E. A. & Osterholm, M. T. COVID-19 and flu, a perfect storm. Science 368, 1163 (2020).","journal-title":"Science"},{"key":"478_CR17","doi-asserted-by":"crossref","unstructured":"Alameh, M. G., Weissman, D. & Pardi, N. Messenger RNA-Based Vaccines Against Infectious Diseases. Curr. Top Microbiol. Immunol. (2020).","DOI":"10.1007\/82_2020_202"},{"key":"478_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","volume":"20","author":"JR Mascola","year":"2020","unstructured":"Mascola, J. R. & Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87\u201388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"478_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre, M. S. et al. Novel approaches for vaccine development. Cell 184, 1589\u20131603 (2021).","journal-title":"Cell"},{"key":"478_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett, K. J. et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids 15, 1\u201311 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"478_CR21","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park, J. W., Lagniton, P. N. P., Liu, Y. & Xu, R.-H. mRNA vaccines for COVID-19: what, why and how. Int. J. Biol. Sci. 17, 1446\u20131460 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"478_CR22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.2021.3199","volume":"325","author":"CB Creech","year":"2021","unstructured":"Creech, C. B., Walker, S. C. & Samuels, R. J. SARS-CoV-2 Vaccines. JAMA 325, 1318\u20131320 (2021).","journal-title":"JAMA"},{"key":"478_CR23","doi-asserted-by":"publisher","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","volume":"10","author":"W Ho","year":"2021","unstructured":"Ho, W. et al. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv. Health. Mater. 10, e2001812 (2021).","journal-title":"Adv. Health. Mater."},{"key":"478_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"478_CR25","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326\u20133334 (2019).","journal-title":"Vaccine"},{"key":"478_CR26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang, N. N. et al. A Thermostable mRNA Vaccine against COVID-19. Cell 182, 1271\u20131283 e1216 (2020).","journal-title":"Cell"},{"key":"478_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41392-021-00861-4","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Signal Transduct. Target Ther. 6, 438 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"478_CR28","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.1016\/S2666-5247(21)00280-9","volume":"3","author":"G-L Chen","year":"2022","unstructured":"Chen, G.-L. et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 3, E193\u2013E202 (2022).","journal-title":"Lancet Microbe"},{"key":"478_CR29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1126\/science.abc4730","volume":"369","author":"H Gu","year":"2020","unstructured":"Gu, H. et al. Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science 369, 1603\u20131607 (2020).","journal-title":"Science"},{"key":"478_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","volume":"39","author":"EL Blanchard","year":"2021","unstructured":"Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717\u2013726 (2021).","journal-title":"Nat. Biotechnol."},{"key":"478_CR31","doi-asserted-by":"publisher","first-page":"e0159821","DOI":"10.1128\/mBio.01598-21","volume":"12","author":"M Nagai","year":"2021","unstructured":"Nagai, M., Moriyama, M. & Ichinohe, T. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. mBio 12, e0159821 (2021).","journal-title":"mBio"},{"key":"478_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"478_CR33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"478_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"478_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4161\/hv.22908","volume":"9","author":"RJ Cox","year":"2013","unstructured":"Cox, R. J. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin Immunother. 9, 405\u2013408 (2013).","journal-title":"Hum. Vaccin Immunother."},{"key":"478_CR36","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(21)00782-0","volume":"397","author":"F Krammer","year":"2021","unstructured":"Krammer, F. Correlates of protection from SARS-CoV-2 infection. Lancet 397, 1421\u20131423 (2021).","journal-title":"Lancet"},{"key":"478_CR37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","volume":"15","author":"CM Trombetta","year":"2016","unstructured":"Trombetta, C. M. & Montomoli, E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev. Vaccines. 15, 967\u2013976 (2016).","journal-title":"Expert Rev. Vaccines."},{"key":"478_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","volume":"51","author":"TJ Ruckwardt","year":"2019","unstructured":"Ruckwardt, T. J., Morabito, K. M. & Graham, B. S. Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. Immunity 51, 429\u2013442 (2019).","journal-title":"Immunity"},{"key":"478_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"478_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"478_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"478_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cmi.2017.02.009","volume":"23","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. & Krammer, F. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol Infect. 23, 222\u2013228 (2017).","journal-title":"Clin. Microbiol Infect."},{"key":"478_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"478_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMp2118468","volume":"386","author":"DM Morens","year":"2021","unstructured":"Morens, D. M., Taubenberger, J. K. & Fauci, A. S Universal Coronavirus Vaccines - An Urgent Need. N. Engl. J. Med 386, 297\u2013299 (2021).","journal-title":"N. Engl. J. Med"},{"key":"478_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0198-1","volume":"5","author":"LT Giurgea","year":"2020","unstructured":"Giurgea, L. T., Han, A. & Memoli, M. J. Universal coronavirus vaccines: the time to start is now. NPJ Vaccines. 5, 43 (2020).","journal-title":"NPJ Vaccines."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00478-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00478-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00478-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:45:31Z","timestamp":1669297531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00478-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00478-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1266195\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"19 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.F.Q., B.Y., Q.Y. and X.L. are co-inventors on pending patent applications related to the AR-CoV\/IAV vaccine. B.Y., X.L., X.Z., D.L., H.S., and Z.L. are employees of Suzhou Abogen Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}